Genomics-assisted stacking of waxy1, opaque2, and crtRB1 genes for enhancing amylopectin in biofortified maize for industrial utilization and nutritional security.

Waxy maize is highly preferred diet in developing countries due to its high amylopectin content. Enriching amylopectin in biofortified maize meets food security and fulfils the demand of rising industrial applications, especially bioethanol. The mutant waxy1 (wx1) gene is responsible for increased amylopectin in maize starch, with a wide range of food and industrial applications.

Comparison of Intraoperative Propofol-Dexmedetomidine and Ketofol-Dexmedetomidine Infusions on Recovery from Anesthesia in Patients Undergoing Endoscopic Trans-Sphenoidal Pituitary Surgeries: A Randomised Controlled Trial.

Background: A rapid and smooth emergence is essential in patients undergoing trans-sphenoidal pituitary surgeries. Ketofol has been used as an anesthetic agent with good recovery characteristics. We conducted this study to compare the recovery profile of the patients receiving propofol-dexmedetomidine or ketofol-dexmedetomidine infusions for trans-sphenoidal excision of pituitary tumours.

Development and Validation of Multiplex-PCR Assay for and Genes Governing Enhanced Multivitamins in Maize for Its Application in Genomics-Assisted Breeding.

Traditional maize possesses low concentrations of provitamin-A and vitamin-E, leading to various health concerns. Mutant alleles of and that enhance β-carotene (provitamin-A) and α-tocopherol (vitamin-E), respectively, in maize kernels have been explored in several biofortification programs. For genetic improvement of these target nutrients, uniplex-PCR assays are routinely used in marker-assisted selection.

Phytochemical strategies in glioblastoma therapy: Mechanisms, efficacy, and future perspectives.

Glioblastoma (GBM) is foremost the most aggressive primary brain tumor, presenting extensive therapeutic challenges due to its high invasiveness, genetic complexity, and resistance to established treatments. Despite substantial advances in surgical and chemotherapeutic interventions, the median survival rate for patients is only 14.6 months, and the prognosis remains poor.

Double Whammy: A Case Report of Immune Checkpoint Inhibitor Colitis and Concomitant Colitis in a Patient on Nivolumab.

Immune checkpoint inhibitors commonly cause gastrointestinal immune-related adverse effects. These patients also carry an increased risk of concomitant infections. This 66-year-old man with immune checkpoint inhibitor colitis was discovered to have concurrent and colitis.